Ahmed O. Kaseb, MD, discusses the significance of results from the phase 3 IMbrave050 trial of adjuvant atezolizumab and bevacizumab for patients with early-stage hepatocellular carcinoma.
Ahmed O. Kaseb, MD
Advertisement
Articles by Ahmed O. Kaseb, MD
Ahmed O. Kaseb, MD, discusses the safety profile of the combination of atezolizumab and bevacizumab in hepatocellular carcinoma.
Ahmed O. Kaseb, MD, a professor in the Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, discusses research with targeted therapy in hepatocellular carcinoma (HCC).
Ahmed O. Kaseb, MD, discusses the progression of therapy options for patients with hepatocellular carcinoma.
Advertisement
Latest Updated Articles
Dr. Kaseb on the Progression of HCC ResearchMarch 11th 2020
Dr. Kaseb on Research With Targeted Therapy in HCCApril 1st 2020
Advertisement
Advertisement
Trending on OncLive
1
ctDNA Status Has Strong Prognostic Value, Outperforming pCR Status, in Early TNBC
2
The OncFive: Top Oncology Articles for the Week of 5/31
3
From Toilet Cleaner to Thoracic Oncologist and Patient: How Ross Camidge Built a Life Worth Loving
4
CELMoDs and Bispecifics Break Through Across Lymphomas and Leukemias at EHA 2026
5